title: siRNA and pharmacological inhibition of endocytic pathways to characterize the differential role of macropinocytosis and the actin cytoskeleton on cellular uptake of dextran and cationic cell penetrating peptides octaarginine (R8) and HIV-Tat.
abstract: Cell penetrating peptides (CPPs) have been extensively studied as vectors for cellular delivery of therapeutic macromolecules. It is widely accepted that they can enter cells directly across the plasma membrane but also gain access through endocytic pathways that are yet to be fully defined. Here we developed siRNA methods in epithelial cell lines, HeLa and A431, to inhibit endocytic pathways regulated by clathrin heavy chain, flotillin-1, caveolin-1, dynamin-2 and Pak-1. In each case, functional uptake assays were developed to characterize the requirement for these proteins, and the pathways they regulate, in the internalisation of defined endocytic probes and also the CPPs octaarginine and HIV-Tat. Peptide uptake was only inhibited in A431 cells depleted of the macropinocytosis regulator Pak-1, but experimental variables including choice of cell line, pharmacological inhibitor, macropinocytic probe and serum starvation significantly influence our ability to assess and assign this pathway as an important route for CPP uptake. Actin disruption with Cytochalasin D inhibited peptide entry in both cell lines but the effects of this agent on dextran uptake was cell line dependent, reducing uptake in HeLa cells and increasing uptake in A431 cells. This was further supported in experiments inducing actin stabilisation by Jasplakinolide, emphasising that the actin cytoskeleton can both promote and hinder endocytosis. Overall the data identify important aspects regarding the comparative mechanisms of CPP uptake and macropinocytosis, and accentuate the significant methodological challenges of studying this pathway as an endocytic portal and an entry route for drug delivery vectors.
authors.affiliation: Cardiff School of Pharmacy and Pharmaceutical Sciences, Redwood Building, Cardiff University, Cardiff, Wales CF10 3NB, United Kingdom.
authors.forename: M
authors.initials: M
authors.lastname: Al Soraj
authors.forename: L
authors.initials: L
authors.lastname: He
authors.forename: K
authors.initials: K
authors.lastname: Peynshaert
authors.forename: J
authors.initials: J
authors.lastname: Cousaert
authors.forename: D
authors.initials: D
authors.lastname: Vercauteren
authors.forename: K
authors.initials: K
authors.lastname: Braeckmans
authors.forename: S C
authors.initials: SC
authors.lastname: De Smedt
authors.forename: A T
authors.initials: AT
authors.lastname: Jones
mesh_terms: D008841:Actin Cytoskeleton / Q000378:metabolism* / Q000648:ultrastructure; D000595:Amino Acid Sequence; D051242:Caveolin 1 / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D057846:Cell-Penetrating Peptides / Q000378:metabolism*; D003911:Dextrans / Q000378:metabolism*; D004705:Endocytosis / Q000187:drug effects*; D004815:Epidermal Growth Factor / Q000235:genetics / Q000378:metabolism; D015696:Gene Products, tat / Q000737:chemistry / Q000378:metabolism; D006678:HIV / Q000737:chemistry / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000378:metabolism; D010873:Pinocytosis / Q000187:drug effects; D034741:RNA, Small Interfering / Q000235:genetics*; D015398:Signal Transduction / Q000187:drug effects; D054462:p21-Activated Kinases / Q000235:genetics / Q000378:metabolism
chemical_list: D051242:Caveolin 1; D057846:Cell-Penetrating Peptides; D003911:Dextrans; D015696:Gene Products, tat; D008565:Membrane Proteins; D009842:Oligopeptides; D034741:RNA, Small Interfering; C106354:flotillins; C448619:octaarginine; D004815:Epidermal Growth Factor; D054462:p21-Activated Kinases